Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models
Animal models for Parkinson's disease (PD) are very useful in understanding the pathogenesis of PD and screening for new therapeutic approaches. The present study compared two commonly used neurotoxin‑induced mouse models of chronic PD to guide model selection, explore the pathogenesis and mech...
Gespeichert in:
Veröffentlicht in: | Molecular medicine reports 2022-03, Vol.25 (3), Article 91 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 3 |
container_start_page | |
container_title | Molecular medicine reports |
container_volume | 25 |
creator | Zhang, Jing Sun, Bohao Yang, Jifeng Chen, Zhuo Li, Zhengzheng Zhang, Nan Li, Hongzhi Shen, Luxi |
description | Animal models for Parkinson's disease (PD) are very useful in understanding the pathogenesis of PD and screening for new therapeutic approaches. The present study compared two commonly used neurotoxin‑induced mouse models of chronic PD to guide model selection, explore the pathogenesis and mechanisms underlying PD and develop effective treatments. The chronic PD mouse models were established via treatment with rotenone or 1‑methyl‑4‑phenyl‑1,2,3,6-tetrahydropyridine (MPTP) for 6 weeks. The effects of rotenone and MPTP in the mice were compared by assessing neurobehavior, neuropathology and mitochondrial function through the use of the pole, rotarod and open field tests, immunohistochemistry for tyrosine hydroxylase (TH), glial fibrillary acidic protein (GFAP), ionized calcium‑binding adapter molecule 1 (Iba‑1), neuronal nuclear antigen (NeuN) and (p)S129 α‑synuclein, immunofluorescence for GFAP, Iba‑1 and NeuN, western blotting for TH, oxygen consumption, complex I enzyme activity. The locomotor activity, motor coordination and exploratory behavior in both rotenone and MPTP groups were significantly lower compared with the control group. However, behavioral tests were no significant differences between the two groups. In the MPTP group, the loss of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta, the reduction of the tyrosine hydroxylase content in the SN and striatum and the astrocyte proliferation and microglial activation in the SN were more significant compared with the rotenone group. Notably, mitochondrial‑dependent oxygen consumption and complex I enzyme activity in the SN were significantly reduced in the rotenone group compared with the MPTP group. In addition, Lewy bodies were present only in SN neurons in the rotenone group. Although no significant differences in neurobehavior were observed between the two mouse models, the MPTP model reproduced the pathological features of PD more precisely in terms of the loss of DA neurons, decreased dopamine levels and neuroinflammation in the SN. On the other hand, the rotenone model was more suitable for studying the role of mitochondrial dysfunction (deficient complex I activity) and Lewy body formation in the SN, which is a characteristic pathological feature of PD. The results indicated that MPTP and rotenone PD models have advantages and disadvantages, therefore one or both should be selected based on the purpose of the study. |
doi_str_mv | 10.3892/mmr.2022.12607 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8809117</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A695364045</galeid><sourcerecordid>A695364045</sourcerecordid><originalsourceid>FETCH-LOGICAL-c551t-c214238b9cdd6210a211913a364d99062d9d736c3ac57d1f5dc043fe350c35da3</originalsourceid><addsrcrecordid>eNptUk1v1DAQjRCIlsKVI4rEgcvu4o_YiS9I1YovqRIc4Gy59mTjEtvBTirtjb_Aif_HL2G2LAWkyrL8xn7zPGO_qnpKyYZ3ir0MIW8YYWxDmSTtveqUtoquOSHN_SNmSrUn1aNSrgiRggn1sDrhgnDVtfK0-rFNYTLZlxTr1NfzADX0Pdj5EOU0Q0wRahNdTX9--x5gHvYjggbnNEC8CeiKrfhKIpphzmbYu5ymffbOYyrq-ugW6-OutkNO0dv6o8lffMQrX5Ta-QKmAJLqkBYEITkYy-PqQW_GAk-O61n1-c3rT9t364sPb99vzy_WVgg6ry2jDePdpbLOSUaJYZQqyg2XjVOKSOaUa7m03FjROtoLZ0nDe8AHsFw4w8-qV791p-UygLMQsYNRT9kHk_c6Ga__P4l-0Lt0rbuOKEpbFHh-FMjp6wJl1ldpyRFr1kyyljeCMvWXtTMjaB_7hGI2-GL1uVQCyyWNQNbmDhYOB8Fb_Ije4_5dCTanUjL0t4VTog_-0OgPffCHvvEHJjz7t91b-h9D8F8nArwx</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627345129</pqid></control><display><type>article</type><title>Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models</title><source>Spandidos Publications Journals</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Zhang, Jing ; Sun, Bohao ; Yang, Jifeng ; Chen, Zhuo ; Li, Zhengzheng ; Zhang, Nan ; Li, Hongzhi ; Shen, Luxi</creator><creatorcontrib>Zhang, Jing ; Sun, Bohao ; Yang, Jifeng ; Chen, Zhuo ; Li, Zhengzheng ; Zhang, Nan ; Li, Hongzhi ; Shen, Luxi</creatorcontrib><description>Animal models for Parkinson's disease (PD) are very useful in understanding the pathogenesis of PD and screening for new therapeutic approaches. The present study compared two commonly used neurotoxin‑induced mouse models of chronic PD to guide model selection, explore the pathogenesis and mechanisms underlying PD and develop effective treatments. The chronic PD mouse models were established via treatment with rotenone or 1‑methyl‑4‑phenyl‑1,2,3,6-tetrahydropyridine (MPTP) for 6 weeks. The effects of rotenone and MPTP in the mice were compared by assessing neurobehavior, neuropathology and mitochondrial function through the use of the pole, rotarod and open field tests, immunohistochemistry for tyrosine hydroxylase (TH), glial fibrillary acidic protein (GFAP), ionized calcium‑binding adapter molecule 1 (Iba‑1), neuronal nuclear antigen (NeuN) and (p)S129 α‑synuclein, immunofluorescence for GFAP, Iba‑1 and NeuN, western blotting for TH, oxygen consumption, complex I enzyme activity. The locomotor activity, motor coordination and exploratory behavior in both rotenone and MPTP groups were significantly lower compared with the control group. However, behavioral tests were no significant differences between the two groups. In the MPTP group, the loss of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta, the reduction of the tyrosine hydroxylase content in the SN and striatum and the astrocyte proliferation and microglial activation in the SN were more significant compared with the rotenone group. Notably, mitochondrial‑dependent oxygen consumption and complex I enzyme activity in the SN were significantly reduced in the rotenone group compared with the MPTP group. In addition, Lewy bodies were present only in SN neurons in the rotenone group. Although no significant differences in neurobehavior were observed between the two mouse models, the MPTP model reproduced the pathological features of PD more precisely in terms of the loss of DA neurons, decreased dopamine levels and neuroinflammation in the SN. On the other hand, the rotenone model was more suitable for studying the role of mitochondrial dysfunction (deficient complex I activity) and Lewy body formation in the SN, which is a characteristic pathological feature of PD. The results indicated that MPTP and rotenone PD models have advantages and disadvantages, therefore one or both should be selected based on the purpose of the study.</description><identifier>ISSN: 1791-2997</identifier><identifier>EISSN: 1791-3004</identifier><identifier>DOI: 10.3892/mmr.2022.12607</identifier><identifier>PMID: 35039876</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine ; Animal models ; Animal models in research ; Animals ; Antibodies ; Antigens ; Avoidance Learning - physiology ; Blotting, Western ; Brain research ; Chronic Disease ; Development and progression ; Disease Models, Animal ; DNA-Binding Proteins - metabolism ; Dopamine receptors ; Dopaminergic Neurons - cytology ; Electron transport chain ; Enzymatic activity ; Experiments ; Exploratory behavior ; Glial fibrillary acidic protein ; Glial Fibrillary Acidic Protein - metabolism ; Humans ; Hydroxylase ; Immunofluorescence ; Immunohistochemistry ; Inflammation ; Laboratory animals ; Lewy bodies ; Locomotor activity ; Medical research ; Mice ; Mice, Inbred C57BL ; Mitochondria ; Motor Activity - physiology ; Movement disorders ; MPTP ; Neostriatum ; Nerve Tissue Proteins - metabolism ; Neurodegenerative diseases ; Neurological research ; Neurons ; Neurotoxic agents ; Older people ; Oxygen consumption ; Parkinson Disease, Secondary - chemically induced ; Parkinson Disease, Secondary - metabolism ; Parkinson Disease, Secondary - physiopathology ; Parkinson's disease ; Pathogenesis ; Rotenone ; Software ; Substantia nigra ; Substantia Nigra - cytology ; Synuclein ; Testing ; Tyrosine 3-Monooxygenase - metabolism ; Western blotting</subject><ispartof>Molecular medicine reports, 2022-03, Vol.25 (3), Article 91</ispartof><rights>COPYRIGHT 2022 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2022</rights><rights>Copyright: © Zhang et al. 2022</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c551t-c214238b9cdd6210a211913a364d99062d9d736c3ac57d1f5dc043fe350c35da3</citedby><cites>FETCH-LOGICAL-c551t-c214238b9cdd6210a211913a364d99062d9d736c3ac57d1f5dc043fe350c35da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35039876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Jing</creatorcontrib><creatorcontrib>Sun, Bohao</creatorcontrib><creatorcontrib>Yang, Jifeng</creatorcontrib><creatorcontrib>Chen, Zhuo</creatorcontrib><creatorcontrib>Li, Zhengzheng</creatorcontrib><creatorcontrib>Zhang, Nan</creatorcontrib><creatorcontrib>Li, Hongzhi</creatorcontrib><creatorcontrib>Shen, Luxi</creatorcontrib><title>Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models</title><title>Molecular medicine reports</title><addtitle>Mol Med Rep</addtitle><description>Animal models for Parkinson's disease (PD) are very useful in understanding the pathogenesis of PD and screening for new therapeutic approaches. The present study compared two commonly used neurotoxin‑induced mouse models of chronic PD to guide model selection, explore the pathogenesis and mechanisms underlying PD and develop effective treatments. The chronic PD mouse models were established via treatment with rotenone or 1‑methyl‑4‑phenyl‑1,2,3,6-tetrahydropyridine (MPTP) for 6 weeks. The effects of rotenone and MPTP in the mice were compared by assessing neurobehavior, neuropathology and mitochondrial function through the use of the pole, rotarod and open field tests, immunohistochemistry for tyrosine hydroxylase (TH), glial fibrillary acidic protein (GFAP), ionized calcium‑binding adapter molecule 1 (Iba‑1), neuronal nuclear antigen (NeuN) and (p)S129 α‑synuclein, immunofluorescence for GFAP, Iba‑1 and NeuN, western blotting for TH, oxygen consumption, complex I enzyme activity. The locomotor activity, motor coordination and exploratory behavior in both rotenone and MPTP groups were significantly lower compared with the control group. However, behavioral tests were no significant differences between the two groups. In the MPTP group, the loss of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta, the reduction of the tyrosine hydroxylase content in the SN and striatum and the astrocyte proliferation and microglial activation in the SN were more significant compared with the rotenone group. Notably, mitochondrial‑dependent oxygen consumption and complex I enzyme activity in the SN were significantly reduced in the rotenone group compared with the MPTP group. In addition, Lewy bodies were present only in SN neurons in the rotenone group. Although no significant differences in neurobehavior were observed between the two mouse models, the MPTP model reproduced the pathological features of PD more precisely in terms of the loss of DA neurons, decreased dopamine levels and neuroinflammation in the SN. On the other hand, the rotenone model was more suitable for studying the role of mitochondrial dysfunction (deficient complex I activity) and Lewy body formation in the SN, which is a characteristic pathological feature of PD. The results indicated that MPTP and rotenone PD models have advantages and disadvantages, therefore one or both should be selected based on the purpose of the study.</description><subject>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</subject><subject>Animal models</subject><subject>Animal models in research</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Avoidance Learning - physiology</subject><subject>Blotting, Western</subject><subject>Brain research</subject><subject>Chronic Disease</subject><subject>Development and progression</subject><subject>Disease Models, Animal</subject><subject>DNA-Binding Proteins - metabolism</subject><subject>Dopamine receptors</subject><subject>Dopaminergic Neurons - cytology</subject><subject>Electron transport chain</subject><subject>Enzymatic activity</subject><subject>Experiments</subject><subject>Exploratory behavior</subject><subject>Glial fibrillary acidic protein</subject><subject>Glial Fibrillary Acidic Protein - metabolism</subject><subject>Humans</subject><subject>Hydroxylase</subject><subject>Immunofluorescence</subject><subject>Immunohistochemistry</subject><subject>Inflammation</subject><subject>Laboratory animals</subject><subject>Lewy bodies</subject><subject>Locomotor activity</subject><subject>Medical research</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mitochondria</subject><subject>Motor Activity - physiology</subject><subject>Movement disorders</subject><subject>MPTP</subject><subject>Neostriatum</subject><subject>Nerve Tissue Proteins - metabolism</subject><subject>Neurodegenerative diseases</subject><subject>Neurological research</subject><subject>Neurons</subject><subject>Neurotoxic agents</subject><subject>Older people</subject><subject>Oxygen consumption</subject><subject>Parkinson Disease, Secondary - chemically induced</subject><subject>Parkinson Disease, Secondary - metabolism</subject><subject>Parkinson Disease, Secondary - physiopathology</subject><subject>Parkinson's disease</subject><subject>Pathogenesis</subject><subject>Rotenone</subject><subject>Software</subject><subject>Substantia nigra</subject><subject>Substantia Nigra - cytology</subject><subject>Synuclein</subject><subject>Testing</subject><subject>Tyrosine 3-Monooxygenase - metabolism</subject><subject>Western blotting</subject><issn>1791-2997</issn><issn>1791-3004</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptUk1v1DAQjRCIlsKVI4rEgcvu4o_YiS9I1YovqRIc4Gy59mTjEtvBTirtjb_Aif_HL2G2LAWkyrL8xn7zPGO_qnpKyYZ3ir0MIW8YYWxDmSTtveqUtoquOSHN_SNmSrUn1aNSrgiRggn1sDrhgnDVtfK0-rFNYTLZlxTr1NfzADX0Pdj5EOU0Q0wRahNdTX9--x5gHvYjggbnNEC8CeiKrfhKIpphzmbYu5ymffbOYyrq-ugW6-OutkNO0dv6o8lffMQrX5Ta-QKmAJLqkBYEITkYy-PqQW_GAk-O61n1-c3rT9t364sPb99vzy_WVgg6ry2jDePdpbLOSUaJYZQqyg2XjVOKSOaUa7m03FjROtoLZ0nDe8AHsFw4w8-qV791p-UygLMQsYNRT9kHk_c6Ga__P4l-0Lt0rbuOKEpbFHh-FMjp6wJl1ldpyRFr1kyyljeCMvWXtTMjaB_7hGI2-GL1uVQCyyWNQNbmDhYOB8Fb_Ije4_5dCTanUjL0t4VTog_-0OgPffCHvvEHJjz7t91b-h9D8F8nArwx</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Zhang, Jing</creator><creator>Sun, Bohao</creator><creator>Yang, Jifeng</creator><creator>Chen, Zhuo</creator><creator>Li, Zhengzheng</creator><creator>Zhang, Nan</creator><creator>Li, Hongzhi</creator><creator>Shen, Luxi</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20220301</creationdate><title>Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models</title><author>Zhang, Jing ; Sun, Bohao ; Yang, Jifeng ; Chen, Zhuo ; Li, Zhengzheng ; Zhang, Nan ; Li, Hongzhi ; Shen, Luxi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c551t-c214238b9cdd6210a211913a364d99062d9d736c3ac57d1f5dc043fe350c35da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</topic><topic>Animal models</topic><topic>Animal models in research</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Avoidance Learning - physiology</topic><topic>Blotting, Western</topic><topic>Brain research</topic><topic>Chronic Disease</topic><topic>Development and progression</topic><topic>Disease Models, Animal</topic><topic>DNA-Binding Proteins - metabolism</topic><topic>Dopamine receptors</topic><topic>Dopaminergic Neurons - cytology</topic><topic>Electron transport chain</topic><topic>Enzymatic activity</topic><topic>Experiments</topic><topic>Exploratory behavior</topic><topic>Glial fibrillary acidic protein</topic><topic>Glial Fibrillary Acidic Protein - metabolism</topic><topic>Humans</topic><topic>Hydroxylase</topic><topic>Immunofluorescence</topic><topic>Immunohistochemistry</topic><topic>Inflammation</topic><topic>Laboratory animals</topic><topic>Lewy bodies</topic><topic>Locomotor activity</topic><topic>Medical research</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mitochondria</topic><topic>Motor Activity - physiology</topic><topic>Movement disorders</topic><topic>MPTP</topic><topic>Neostriatum</topic><topic>Nerve Tissue Proteins - metabolism</topic><topic>Neurodegenerative diseases</topic><topic>Neurological research</topic><topic>Neurons</topic><topic>Neurotoxic agents</topic><topic>Older people</topic><topic>Oxygen consumption</topic><topic>Parkinson Disease, Secondary - chemically induced</topic><topic>Parkinson Disease, Secondary - metabolism</topic><topic>Parkinson Disease, Secondary - physiopathology</topic><topic>Parkinson's disease</topic><topic>Pathogenesis</topic><topic>Rotenone</topic><topic>Software</topic><topic>Substantia nigra</topic><topic>Substantia Nigra - cytology</topic><topic>Synuclein</topic><topic>Testing</topic><topic>Tyrosine 3-Monooxygenase - metabolism</topic><topic>Western blotting</topic><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Jing</creatorcontrib><creatorcontrib>Sun, Bohao</creatorcontrib><creatorcontrib>Yang, Jifeng</creatorcontrib><creatorcontrib>Chen, Zhuo</creatorcontrib><creatorcontrib>Li, Zhengzheng</creatorcontrib><creatorcontrib>Zhang, Nan</creatorcontrib><creatorcontrib>Li, Hongzhi</creatorcontrib><creatorcontrib>Shen, Luxi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular medicine reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Jing</au><au>Sun, Bohao</au><au>Yang, Jifeng</au><au>Chen, Zhuo</au><au>Li, Zhengzheng</au><au>Zhang, Nan</au><au>Li, Hongzhi</au><au>Shen, Luxi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models</atitle><jtitle>Molecular medicine reports</jtitle><addtitle>Mol Med Rep</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>25</volume><issue>3</issue><artnum>91</artnum><issn>1791-2997</issn><eissn>1791-3004</eissn><abstract>Animal models for Parkinson's disease (PD) are very useful in understanding the pathogenesis of PD and screening for new therapeutic approaches. The present study compared two commonly used neurotoxin‑induced mouse models of chronic PD to guide model selection, explore the pathogenesis and mechanisms underlying PD and develop effective treatments. The chronic PD mouse models were established via treatment with rotenone or 1‑methyl‑4‑phenyl‑1,2,3,6-tetrahydropyridine (MPTP) for 6 weeks. The effects of rotenone and MPTP in the mice were compared by assessing neurobehavior, neuropathology and mitochondrial function through the use of the pole, rotarod and open field tests, immunohistochemistry for tyrosine hydroxylase (TH), glial fibrillary acidic protein (GFAP), ionized calcium‑binding adapter molecule 1 (Iba‑1), neuronal nuclear antigen (NeuN) and (p)S129 α‑synuclein, immunofluorescence for GFAP, Iba‑1 and NeuN, western blotting for TH, oxygen consumption, complex I enzyme activity. The locomotor activity, motor coordination and exploratory behavior in both rotenone and MPTP groups were significantly lower compared with the control group. However, behavioral tests were no significant differences between the two groups. In the MPTP group, the loss of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta, the reduction of the tyrosine hydroxylase content in the SN and striatum and the astrocyte proliferation and microglial activation in the SN were more significant compared with the rotenone group. Notably, mitochondrial‑dependent oxygen consumption and complex I enzyme activity in the SN were significantly reduced in the rotenone group compared with the MPTP group. In addition, Lewy bodies were present only in SN neurons in the rotenone group. Although no significant differences in neurobehavior were observed between the two mouse models, the MPTP model reproduced the pathological features of PD more precisely in terms of the loss of DA neurons, decreased dopamine levels and neuroinflammation in the SN. On the other hand, the rotenone model was more suitable for studying the role of mitochondrial dysfunction (deficient complex I activity) and Lewy body formation in the SN, which is a characteristic pathological feature of PD. The results indicated that MPTP and rotenone PD models have advantages and disadvantages, therefore one or both should be selected based on the purpose of the study.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>35039876</pmid><doi>10.3892/mmr.2022.12607</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1791-2997 |
ispartof | Molecular medicine reports, 2022-03, Vol.25 (3), Article 91 |
issn | 1791-2997 1791-3004 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8809117 |
source | Spandidos Publications Journals; MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Animal models Animal models in research Animals Antibodies Antigens Avoidance Learning - physiology Blotting, Western Brain research Chronic Disease Development and progression Disease Models, Animal DNA-Binding Proteins - metabolism Dopamine receptors Dopaminergic Neurons - cytology Electron transport chain Enzymatic activity Experiments Exploratory behavior Glial fibrillary acidic protein Glial Fibrillary Acidic Protein - metabolism Humans Hydroxylase Immunofluorescence Immunohistochemistry Inflammation Laboratory animals Lewy bodies Locomotor activity Medical research Mice Mice, Inbred C57BL Mitochondria Motor Activity - physiology Movement disorders MPTP Neostriatum Nerve Tissue Proteins - metabolism Neurodegenerative diseases Neurological research Neurons Neurotoxic agents Older people Oxygen consumption Parkinson Disease, Secondary - chemically induced Parkinson Disease, Secondary - metabolism Parkinson Disease, Secondary - physiopathology Parkinson's disease Pathogenesis Rotenone Software Substantia nigra Substantia Nigra - cytology Synuclein Testing Tyrosine 3-Monooxygenase - metabolism Western blotting |
title | Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T14%3A11%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20the%20effect%20of%20rotenone%20and%201%E2%80%91methyl%E2%80%914%E2%80%91phenyl%E2%80%911,2,3,6%E2%80%91tetrahydropyridine%20on%20inducing%20chronic%20Parkinson's%20disease%20in%20mouse%20models&rft.jtitle=Molecular%20medicine%20reports&rft.au=Zhang,%20Jing&rft.date=2022-03-01&rft.volume=25&rft.issue=3&rft.artnum=91&rft.issn=1791-2997&rft.eissn=1791-3004&rft_id=info:doi/10.3892/mmr.2022.12607&rft_dat=%3Cgale_pubme%3EA695364045%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627345129&rft_id=info:pmid/35039876&rft_galeid=A695364045&rfr_iscdi=true |